Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DPP4 | P27487 | 4/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2896482 | 0.82 | DPP4 (0.56) | HSD17B10DPP4DPP8DPP9 | |
| SCHEMBL240005 | 0.82 | DPP4 (0.56) | HSD17B10DPP4DPP8DPP9 | |
| SCHEMBL1357066 | 0.82 | DPP4 (0.56) | HSD17B10DPP4DPP8DPP9 | |
| SCHEMBL2709179 | 0.81 | DPP4 (0.45) | HSD17B10DPP4DPP8DPP9 | |
| SCHEMBL2709181 | 0.81 | DPP4 (0.45) | HSD17B10DPP4DPP8DPP9 | |
| SCHEMBL2709884 | 0.81 | DPP4 (0.45) | HSD17B10DPP4DPP8DPP9 | |
| SCHEMBL2709888 | 0.81 | DPP4 (0.45) | HSD17B10DPP4DPP8DPP9 | |
| SCHEMBL8469269 | 0.81 | HSD17B10 (0.53) | HSD17B10MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL5490029 | 0.81 | MEN1 (0.49) | MEN1ALDH1A1MAPTKMT2ADPP4 | |
| SCHEMBL2710411 | 0.81 | DPP4 (0.51) | HSD17B10DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030225102-A1 | Novel compounds and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225102-A1 | Novel compounds and therapeutic uses thereof | GPR119, SLC5A1, SLC2A4 | HSD17B10 1596/4885MEN1 2227/4885ALDH1A1 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.